Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Share $0.00001 par value
-
Shares outstanding
-
50,588,235
-
Total 13F shares
-
48,815,898
-
Share change
-
-2,031,356
-
Total reported value
-
$548,690,907
-
Put/Call ratio
-
0.09%
-
Price per share
-
$11.24
-
Number of holders
-
116
-
Value change
-
-$21,251,604
-
Number of buys
-
42
-
Number of sells
-
59
Institutional Holders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) as of Q4 2023
As of 31 Dec 2023,
Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) was held by
116 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,815,898 shares.
The largest 10 holders included
Weiss Asset Management LP, BAUPOST GROUP LLC/MA, Madison Avenue Partners, LP, BlackRock Inc., VANGUARD GROUP INC, Irenic Capital Management LP, Pictet Asset Management Holding SA, Newtyn Management, LLC, STATE STREET CORP, and Oasis Management Co Ltd..
This page lists
116
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.